Agarwal Arjun
SEC CIK 2033974 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | SVP, Fin | 14.2K | — | $4.33M | 14 | 2026-01-23 | 2026-09-21 |
Most active insiders at ORKA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir, 10% | — | $300.01M |
| 2 | Dambkowski Carl | Dir | — | $8.65M |
| 3 | Klein Lawrence Otto | CEO, Dir | — | $7.31M |
| 4 | Quinlan Paul T | GC | — | $6.76M |
| 5 | Goncalves Joana | Chief Medical Off | — | $4.54M |
| 6 | Agarwal Arjun | SVP, Fin | — | $4.33M |
| 7 | Sandler Laura Lee | COO | — | $1.94M |
| 8 | Edwards Larry Todd | Chief Commercial Off | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-21 17:38 | 2026-09-21 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale | $95.75 | -533 | 14.2K | -4% | -$51.0K |
| DMT | 2026-09-15 19:17 | 2026-09-11 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | M - OptEx | $15.88 | +9,459 | 24.8K | +62% | +$150.2K |
| DMT | 2026-09-15 19:17 | 2026-09-11+ | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale+OE | $92.43 | -10.0K | 14.8K | -40% | -$926.0K |
| DMT | 2026-08-14 17:42 | 2026-08-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | M - OptEx | $15.69 | +10.0K | 25.3K | +65% | +$156.9K |
| DMT | 2026-08-14 17:42 | 2026-08-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale+OE | $106.66 | -10.0K | 15.3K | -40% | -$1.07M |
| DMT | 2026-07-13 17:09 | 2026-07-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | M - OptEx | $15.69 | +9,999 | 25.3K | +65% | +$156.9K |
| DMT | 2026-07-13 17:09 | 2026-07-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale+OE | $84.63 | -9,999 | 15.3K | -40% | -$846.2K |
| MT | 2026-06-22 19:59 | 2026-06-22 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale | $80.95 | -1,587 | 15.3K | -9% | -$128.5K |
| DMT | 2026-06-15 18:57 | 2026-06-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | M - OptEx | $15.88 | +9,459 | 26.8K | +55% | +$150.2K |
| DMT | 2026-06-15 18:57 | 2026-06-12+ | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale+OE | $69.72 | -9,854 | 16.9K | -37% | -$687.0K |
| DMT | 2026-05-18 18:07 | 2026-05-18 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | M - OptEx | $28.80 | +7,833 | 26.7K | +42% | +$225.6K |
| DMT | 2026-05-18 18:07 | 2026-05-18 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale+OE | $59.07 | -10.3K | 16.4K | -39% | -$607.8K |
| 2026-03-17 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | S - Sale | $41.30 | -395 | 18.9K | -2% | -$16.3K | |
| D | 2026-01-23 | 2026-01-23 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Fin | A - Grant | $0.00 | +17.5K | 19.3K | +995% | $0 |
Purchase Sale Sale after option exercise All abbreviations